In fact, the use of a chimeric IL2/IL33 protein was shown to be protective in renal injury (159) and monoclonal anti-IL-33 antibodies where shown to excert promising effects in the control of atopic dermatitis. The gene discussed is IL2; the disease is atopic eczema.